Legend Biotech Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LEGN in the last 30 days.
See all $LEGN insider activity →Legend Biotech (LEGN) highlighted its CAR-T therapy CARVYKTI for multiple myeloma, expanding manufacturing, and in vivo CAR-T approaches. The company projects $2.2B revenue and $464.7M earnings by 2029, requiring 20.2% yearly revenue growth. Analysts caution about concentration risks and competition.
Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M, up from $255.1M, and net income of $33.2M, reversing a prior loss. H1 2026 revenue was $692.6M, with net loss reduced to $21.1M. The company projects $2.2B revenue and $464.7M earnings by 2029. Analysts highlight CARVYKTI's role in profitability and pipeline assets. Management changes and CARVYKTI's dominance remain key risks.
Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M and net income of $33.2M, reversing a year-earlier loss. The stock has declined 38.5% over 1 year and 68.3% over 3 years, but is up 1.9% year-to-date. Analysts suggest the stock may be undervalued at $21.92, with a fair value estimate of $54.23, citing growth potential in multiple myeloma treatments and expansion opportunities.
Over the past 7 days, alphai's AI scored 1 news story mentioning LEGN (Legend Biotech Corp). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent LEGN coverage spans earnings, financial news and corporate actions.
No immediate price impact; the piece is a qualitative overview.
Legend Biotech posted a surprise profit, improving earnings visibility and potentially supporting a price rally.
Profitability surprise may prompt short‑term buying pressure and re‑rating by analysts.
The analyst target hike is a near-term sentiment tailwind, but it is not a new fundamental disclosure beyond the rating change.
Lock-up expiration increases near-term float and potential sell pressure, which can pressure the stock around the release window.
alphai scores every news story that mentions LEGN with an AI model for sentiment and relevance, and aggregates insider trades from Legend Biotech Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Legend Biotech (LEGN) highlighted its CAR-T therapy CARVYKTI for multiple myeloma, expanding manufacturing, and in vivo CAR-T approaches. The company projects $2.2B revenue and $464.7M earnings by 2029, requiring 20.2% yearly revenue growth. Analysts caution about concentration risks and competition.
3 min readLegend Biotech (LEGN) reported Q2 2026 revenue of $387.5M, up from $255.1M, and net income of $33.2M, reversing a prior loss. H1 2026 revenue was $692.6M, with net loss reduced to $21.1M. The company projects $2.2B revenue and $464.7M earnings by 2029. Analysts highlight CARVYKTI's role in profitability and pipeline assets. Management changes and CARVYKTI's dominance remain key risks.
2 min readLegend Biotech (LEGN) reported Q2 2026 revenue of $387.5M and net income of $33.2M, reversing a year-earlier loss. The stock has declined 38.5% over 1 year and 68.3% over 3 years, but is up 1.9% year-to-date. Analysts suggest the stock may be undervalued at $21.92, with a fair value estimate of $54.23, citing growth potential in multiple myeloma treatments and expansion opportunities.
3 min readMorgan Stanley raised its price target on Legend Biotech (LEGN) to $49 from $48 and maintained an Overweight rating, according to TipRanks. The note highlights continued support from CARVYKTI momentum and valuation, with an unchanged $65 target cited in related coverage.
1 min readLegend Biotech Corporation disclosed that certain restricted share units held by executive officers, directors, and a shareholder are under a 60-day lock-up ending 16 Aug 2026, starting 17 Jun 2026. After the lock-up, about 175 million ordinary shares (including ADSs) may enter public sale; total shares outstanding are 386,879,583.
2 min readFierce Pharma Asia reports Legend Biotech’s first profitable quarter, with $63M adjusted net income for the three months ended June, as it expands Carvykti. Taiho and Cullinan’s zipalertinib posted a positive phase 3 in EGFR exon 20-mutated NSCLC. WuXi AppTec won a preliminary injunction against a U.S. DoD blacklist designation.
7 min readLegend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657M (+50% YoY), with U.S. $472M (+32%) and ex-U.S. $185M (+128%). Total revenue was $387.5M (+52%), adjusted net income $63.1M ($0.16/share), and cash $965M. Q3 gross margin guidance was lower-50% range.
6 min read24/7 Wall St. lists Wednesday analyst research calls. Upgrades include Hilton (HLT) to Buy with a $365 target, Intuitive Surgical (ISRG) to Outperform with a $500 target, Merck (MRK) to Outperform with a $143 target, and Okta (OKTA) to Outperform with a $170 target. Downgrades include The Gap (GAP) to Hold, and Novo Nordisk (NVO) to Hold. Initiations cover Genmab (GMAB) and Marriott (MAR).
6 min readLegend Biotech (LEGN) fell 2.4% in pre-open trading after a Q2 2026 earnings beat. Adjusted EPS was $0.16 versus $0.07 consensus, and revenue was $387.5 million versus $362.81 million expected, with the company reporting its first quarter of company-wide profitability. Oppenheimer downgraded it to Perform and cut its price target to $40 from $75, citing competitive pressure on CARVYKTI and limited near-term catalysts.
4 min readLegend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657 million, up 50% YoY. Total revenue was $387.5 million, up 52% YoY, with adjusted net income of $63.1 million ($0.16/share). Cash was $965 million. Q3 gross margin guidance was in the lower 50% range.
7 min read
